[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ureteral-stent-related-symptom\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ureteral-stent-related-symptom":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100587615","phase-1-dexamethasone-for-ureteral-stent-symptoms-dusts-100587615",false,"NCT06930690","Dexamethasone for Ureteral STent Symptoms (DUSTS)","Dexamethasone for Ureteral STent Symptoms (DUSTS): A Randomized, Double-blinded Controlled Study","DUSTS","Inclusion Criteria:\n\n1. Age 18-70 years old\n2. Patients who are undergoing unilateral retrograde ureteroscopy (semi-rigid or flexible) with planned ureteral stent placement for treatment of renal\u002Fureteral stones\n3. Patients who can read and understand English\n4. Patients who can follow up post-operatively within 7 days at Houston Methodist Hospital\n\nExclusion Criteria:\n\n1. Untreated UTI\n2. HbA1c ≥6.5 on preoperative testing\n3. Patients with prior diagnosis of any type of diabetes mellitus\n4. Patients with immunosuppression, including chronic corticosteroid use\n5. Patients with bleeding disorder\n6. Patients with chronic liver disease, cirrhosis, and liver failure.\n7. Patients taking strong CYP3A4 inducers or inhibitors within two weeks of screening\n8. Chronic opioid analgesic use\n9. Congenital renal abnormalities (e.g. pelvic kidney, ureteric duplication) that may impair stent placement\n10. Concurrent genitourinary malignancy\n11. Urinary diversion\n12. Renal transplantation\n13. History of interstitial cystitis\u002Fpainful bladder syndrome, prostatitis, pelvic pain due to other conditions (e.g. endometriosis)\n14. Neurologic disorder (e.g. spinal cord injury, multiple sclerosis, spina bifida)\n15. Pregnant or breastfeeding\n16. Patients with cognitive impairments or untreated psychiatric illness","ALL","18 Years","70 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The purpose of this study to learn if high-dose dexamethasone, a type of long-acting steroid, works to decrease urinary symptoms and pain after ureteroscopy and stent placement for kidney stones. The main question it aims to answer is:\n\n1\\) Does high-dose steroid change the quality of life score on day 2 after surgery\n\nResearchers will compare high-dose of dexamethasone (20 mg) to a standard dose of dexamethasone (4 mg) to see if a higher dose of the drug will help with urinary symptoms and pain\n\nParticipants will:\n\n1. randomly receive 20 mg or 4 mg of dexamethasone (20 mg) at the time of surgery\n2. fill out a questionnaire day 1 and day 2 after surgery\n3. fill out a medication diary for one week after surgery\n4. visit the clinic on day 2 after surgery for checkup\n5. visit the clinic on day 4-7 after surgery for check up",[29],"Ureteral Stent-Related Symptom",[31,32,33,29],"Ureteral Stent","Nephrolithiasis","Ureteral Stent Discomfort","RECRUITING","2026-05-27",{"date":37,"type":38},"2026-05-29","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2027-04",{"name":44,"class":45},"The Methodist Hospital Research Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100639550","stent-related-symptoms-defined-by-ureteral-stent-symptom-questionnaire-in-patients-with-image-informed-ureteral-stent-lengths-100639550","NCT07580963","Stent Related Symptoms Defined by Ureteral Stent Symptom Questionnaire in Patients With Image-Informed Ureteral Stent Lengths","Inclusion Criteria:\n\n1. Male or female age 18-80 years\n2. Urolithiasis requiring ureteroscopic management with ureteral stent placement\n3. CT scan showing evidence of upper tract urolithiasis\n4. Negative pre-operative urine culture\n5. No symptoms of urinary tract infection\n\nExclusion Criteria:\n\n1. Known urinary tract anatomical abnormality, reconstructed urinary system, or congenital anomaly\n2. Ureteral stent inserted within the last 31 days\n3. History of peptic ulcer disease, symptomatic benign prostatic hyperplasia, interstitial cystitis, chronic pelvic pain syndrome, neurogenic lower urinary tract dysfunction, ureteral stricture disease\n4. Chronic narcotic use\n5. Allergy to non-steroidal anti-inflammatory medications\n6. Documentation of urinary tract infection within the last 31 days\n7. Pregnant\n8. Surgery being performed on transplanted kidney\n9. Unable to understand the questionnaire\n10. Requiring metallic stent placement\n11. Requiring bilateral or long-term stent insertion\n12. Requiring stent insertion after open or percutaneous renal procedures","80 Years",{"count":55,"type":22},128,[57],"NA","Placement of a ureteral stent at the end of ureteroscopy is commonly performed in endourology. The purpose of this study is to determine whether ureteral stents whose lengths are calibrated to a participant's specific ureteral length based on imaging are better tolerated than one-size-fits-all variable length ureteral stents. The investigators hypothesize that ureteral stent lengths calibrated to the ureteral length of each participant will be better tolerated.",[29],"NOT_YET_RECRUITING","2026-05-05",{"date":63,"type":38},"2026-05-12",{"date":65,"type":22},"2026-05",{"date":67,"type":22},"2027-06",{"name":69,"class":45},"Weill Medical College of Cornell University",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100577802","phase-3-study-of-tamsulosin-solifenacin-and-mirabegron-in-alleviating-ureteral-stent-related-symptoms-100577802","NCT06803030","Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms","A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial","Inclusion Criteria:\n\n• Eligible participants were adult patients (aged 19-80 years) who underwent unilateral retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteric stent insertion for urinary tract stones\n\nExclusion Criteria:\n\n* Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics\n* Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy\n* Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases\n* Preoperative febrile Urinary Tract Infection (UTI)\n* Pregnancy or breastfeeding;\n* A single kidney\n* Moderate or severe cardiovascular or cerebrovascular disease\n* Hepatic dysfunction\n* History of pelvic surgery or irradiation\n* History of bladder or prostate surgery\n* Other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the Ureteral Stent Symptom Questionnaire(USSQ) pain score\n* Allergy to any medication",{"count":78,"type":22},189,[80],"PHASE3","A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.",[29],[84,85,86],"Mirabegron","Tamsulosin","Solifenacin","2025-08-30",{"date":89,"type":38},"2025-09-08",{"date":87,"type":38},{"date":92,"type":22},"2026-12-31",{"name":94,"class":95},"Bir Hospital","OTHER_GOV"]